ClinicalTrials.Veeva

Menu

Pregabalin In Partial Seizures Extension Study (PREPS EXT)

Viatris logo

Viatris

Status and phase

Completed
Phase 3

Conditions

Seizures

Treatments

Drug: Pregabalin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00143130
A0081015

Details and patient eligibility

About

To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.

Enrollment

227 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • met the inclusion/exclusion criteria for A0081005
  • have completed the 21-week study and have shown a significant clinical response and wish to continue treatment

Exclusion criteria

  • Having a treatable cause of seizure.
  • Having a progressive neurological or systemic disorder

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

227 participants in 1 patient group

Single Arm
Experimental group
Treatment:
Drug: Pregabalin

Trial contacts and locations

47

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems